Alnylam Pharmaceuticals
Alnylam has pioneered RNAi therapeutics - and innovative new class of medicines based on RNA interference (RNAi) - a breakthrough discovery in biology that was awarded the Nobel Prize in Medicine and Physiology. RNAi therapeutics work by silencing the genes that cause or contribute to diseases.
Our vision is to harness the potential of RNAi therapeutics to transform the lives of people living with both rare and more common diseases. We are relentless in our pursuit of new treatments. Because patients shouldn’t have to wait for hope.
Alnylam is a global and diverse company of more than 2,000 employees in 26 countries. We are based in Cambridge, Massachusetts, USA.
We encourage you to learn more about our science, pipeline, programs and career opportunities at http://www.alnylam.com/
Ферментативная лигационная платформа siRELIS™ от компании Alnylam
Alnylam Challengers: Improving Access to Healthcare in Boston by Investing in Care Navigators
RNAi, una prometedora plataforma para el desarrollo de fármacos
Alnylam & RNAi Therapeutics: Making our Medicines
Alnylam Act - No Charge, Third Party Genetic Testing & Counseling
Caregiver Perspectives: Jackie and Colin, Primary Hyperoxaluria Type 1 (PH1)
Marc – Living with Wild-Type ATTR Amyloidosis with Cardiomyopathy
Alnylam & RNAi Therapeutics: Silencing Disease. Amplifying Life.
Ben, Lebt Mit AHP
Stephanie, Atteinte de PHA
Marion, Atteinte de PHA
Isabelle, Atteinte de PHA
Découvrez Alnylam – Leader dans le développement des ARNi thérapeutiques
RNAi Therapeutics - How this New Class of Medicines Works
Conheça Alnylam - O Líder em Terapêutica RNAi
Tsuyoshi's Story - トランスサイレチン型家族性アミロイドポリニューロパチーと共に生きる（ショートバージョン）
Tsuyoshi's Story - トランスサイレチン型家族性アミロイドポリニューロパチーと共に生きる（ロングバージョン）
Sue - Living with Acute Hepatic Porphyria (AHP)
Alicia - Living with Acute Hepatic Porphyria (AHP)
How do RNAi Therapeutics Treat Disease?
RNAi, vielversprechendes Potenzial für eine neue Klasse von Medikamenten
Lernen Sie Alnylam kennen - ein führendes Unternehmen in RNAi-Therapeutika
We Asked the Kids of Alnylam...
Alnylam（アルナイラム）企業紹介 - RNAi治療のリーディングカンパニー
Alnylam Challengers Health Equity Symposium 2024
Pathophysiology of Acute Hepatic Porphyria (AHP)
Get to Know Alnylam - The Leader in RNAi Therapeutics
Kim – Living with Primary Hyperoxaluria Type 1